Investment Type: Venture Capital
Mentions in press and media 6
| Date | Title | Description |
| 22.08.2013 | MicuRx Pharmaceuticals Raises $25M in Series B Financing | MicuRx Pharmaceuticals, Inc., a Hayward, CA-based biopharmaceutical company developing innovative antibiotics, raised $25m in Series B financing. The round was led by BVCF, with participation from existing investors Morningside Group and De... |
| 25.10.2012 | MicuRx and Shanghai Zhangjiang Biomedical Industry Venture Capital Partner to Develop Next-generation Antibiotic MRX-I for Chinese Market | -- Joint Venture Shanghai MengKe Pharmaceuticals, Inc. Established-- HAYWARD, Calif. and SHANGHAI, Oct. 24, 2012 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics... |
| 23.07.2012 | Drug alternative to dialysis in kidney, liver failure gets $5.3 million | Industry: Pharmaceuticals Solution/Product: ZS-9, an oral sorbent technology platform that will first be applied to removing toxins in patients suffering from hyperkalemia, or high levels of potassium in the blood, as a result of kidney and... |
| 22.02.2012 | Magnetic therapy for peripheral artery disease gets $7 million | The treatment involves magnetically guided nanoparticles that deliver drugs to diseased blood vessels for the treatment of peripheral artery disease. The initial product Vascular Magnetics is developing uses Paclitaxel, an antirestenosis dr... |
| - | Magnetic therapy for peripheral artery disease gets $7 million | A therapeutics company that has developed a magnetic drug-delivery therapy to treat peripheral artery disease has received a $7 million venture capital investment in a series A financing round. Devon Park Bioventures, a Wayne, Pennsylvania ... |
| - | Drug alternative to dialysis in kidney, liver failure gets $5.3 million | Company Name: ZS Pharma Inc. Location: Ft. Worth, Texas Industry: Pharmaceuticals Solution/Product: ZS-9, an oral sorbent technology platform that will first be applied to removing toxins in patients suffering from hyperkalemia, or high lev... |